U.K. To Decide On Lipitor Patent Wednesday

Law360, New York (October 10, 2005, 12:00 AM EDT) -- In a case that foreshadows one of the most closely watched patent lawsuits in the U.S., a U.K. judge will rule Wednesday on Ranbaxy’s patent challenge to the world’s most widely prescribed drug, Pfizer’s cholesterol fighter Lipitor.

If Pfizer’s patent assertion is denied and Ranbaxy is permitted to produce a generic version, Pfizer stands to lose billions of dollars. The U.K. represents about 7% of the global market for Lipitor.

Globally, Lipitor had sales of $10.3 billion last year, by far overshadowing sales of runner-up Zocor,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.